Introduction

Hip pain linked to labral tears and early cartilage wear is a common reason people seek a specialist opinion. The question most patients arrive with is practical: is there something that can support or repair the joint without a major operation? The answer depends on what is actually damaged, how extensive it is, and how the hip is functioning overall. Two distinct pathways exist at the London Cartilage Clinic — a non-surgical ChondroFiller injection and the Liquid Cartilage keyhole surgical protocol — and they are not the same thing.

Understanding Labral Tears and Early Hip Arthritis

The labrum is a ring of fibrocartilage that deepens the hip socket, contributes to joint stability, and helps distribute load evenly across the femoral head. When the labrum tears — most often from repetitive twisting or impact in sport, or from underlying bony anatomy such as femoroacetabular impingement — the joint's load distribution changes. Over time this can accelerate cartilage wear on the acetabular or femoral surfaces.

Early arthritis of the hip refers to cartilage thinning or focal defects before the joint space has narrowed significantly. At this stage the bone structure is still preserved and the joint remains viable for repair-oriented treatment, making early assessment important. Once cartilage loss is advanced or the joint is globally worn, joint-preservation options become less appropriate.

Two Distinct Approaches: Injection or Keyhole Surgery

Understanding the difference between the two regenerative options offered at the London Cartilage Clinic is important for setting realistic expectations.

The ChondroFiller Injection — Non-Surgical

ChondroFiller is a Class III CE-marked medical device: an acellular type I collagen hydrogel scaffold made by Meidrix Biomedicals in Germany. When used as a non-surgical treatment, it is delivered as an ultrasound-guided outpatient injection — no theatre, no general anaesthetic, no incision. Using imaging to guide accurate placement, the collagen gel is injected directly into the hip joint. Once in position it self-gels within a few minutes, forming a porous three-dimensional matrix that recruits the body's own progenitor cells and may support cartilage repair over time.

The ChondroFiller injection is best suited to earlier cases where the joint is still well-aligned and structurally stable, and where the cartilage damage is limited rather than focal and deep. It acts as a biological support layer rather than a structural repair. Outcomes vary and no guarantee of cartilage restoration can be offered; the injection is not a cure for arthritis.

The Liquid Cartilage Protocol — Keyhole Surgery

Liquid Cartilage is not a product and is not an injection. It is Professor Paul Y. F. Lee's keyhole (arthroscopic) surgical protocol — also known as the Lee Liquid Cartilage Protocol — which uses the ChondroFiller scaffold as its core material but combines it with biological adjuncts and a structured surgical technique to address focal chondral defects in load-bearing joints such as the hip.

The procedure takes place under anaesthetic in a theatre setting. During hip arthroscopy, the defect is prepared with stable vertical margins and the joint chamber is dried using carbon dioxide insufflation. The ChondroFiller scaffold is then applied into the defect and allowed to gel in the dry environment. Biological adjuncts — including platelet-rich fibrin, platelet-rich plasma, and tranexamic acid — are used to prime the defect surface and reinforce the scaffold once it has set. Where indicated, the patient's own mesenchymal stem cells from bone-marrow aspirate concentrate or micro-fragmented adipose tissue may be added to enhance the regenerative environment. A structured rehabilitation programme follows, with protected weight-bearing in the early weeks.

The Liquid Cartilage protocol is indicated for more substantial focal chondral damage — the kind often seen alongside labral pathology in a deep load-bearing joint — where a non-surgical injection alone is unlikely to achieve adequate defect filling or durable repair.

What the Evidence Suggests

ChondroFiller is the device behind both pathways, and its clinical evidence base belongs to the scaffold itself. In published hip series, modified Harris Hip Score has improved by more than 30 points following ChondroFiller-based treatment. MRI assessment of repair tissue using MOCART scoring in hip cases has reached around 80 and above, indicating good defect filling and tissue quality. These outcomes reflect the scaffold's performance in a hip environment; the Liquid Cartilage surgical protocol is designed to optimise the conditions under which this regeneration takes place.

Evidence from small joint applications — including trapeziometacarpal osteoarthritis — further supports the scaffold's ability to reduce pain and improve function across different joint contexts. As with any regenerative approach, results vary between individuals and the evidence base continues to develop; the approach is relatively new compared with established surgical techniques.

Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.

Is This Approach Right for You?

Suitability for either pathway depends on thorough clinical assessment, including examination, functional testing, and imaging. Broadly:

• The ChondroFiller injection may suit patients with early, diffuse cartilage support needs in a structurally stable hip, who are looking for a non-surgical biological option with realistic expectations.
• The Liquid Cartilage surgical protocol is more likely to be appropriate where there is a focal chondral defect alongside labral pathology, the joint can still be preserved, and the patient can commit to the post-operative rehabilitation required.
• Neither approach is appropriate where arthritis is advanced, joint alignment is severely compromised, or surgical fitness is a concern.

A detailed assessment allows a specialist to advise honestly on whether either pathway offers a realistic benefit for a given patient's hip, or whether other management is more appropriate.

Conclusion

Hip pain from labral tears and early arthritis can be difficult to manage, but regenerative options — both non-surgical and surgical — have developed significantly. ChondroFiller, as the CE-marked collagen scaffold, underpins both the outpatient injection and the Liquid Cartilage keyhole surgical protocol. They are not interchangeable: one is a clinic-based injection, the other is genuine keyhole surgery with biological augmentation. Getting the right recommendation means understanding which, if either, matches the nature and extent of the damage. At the London Cartilage Clinic, assessment with a cartilage specialist is the starting point for that conversation.